Plus Therapeutics, Inc.
PSTV
$6.14
$0.549.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.37M | 1.40M | 1.39M | 1.06M | 1.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.37M | 1.40M | 1.39M | 1.06M | 1.41M |
| Cost of Revenue | 2.94M | 2.44M | 1.25M | 1.76M | 2.19M |
| Gross Profit | -1.57M | -1.04M | 144.00K | -697.00K | -774.00K |
| SG&A Expenses | 4.17M | 3.44M | 1.68M | 2.84M | 3.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.11M | 5.88M | 2.93M | 4.60M | 5.31M |
| Operating Income | -5.74M | -4.48M | -1.54M | -3.54M | -3.90M |
| Income Before Tax | -5.71M | -4.42M | 5.15M | -17.40M | -3.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.71M | -4.42M | 5.15M | -17.40M | -3.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.71M | -4.42M | 5.15M | -17.40M | -3.90M |
| EBIT | -5.74M | -4.48M | -1.54M | -3.54M | -3.90M |
| EBITDA | -5.60M | -4.41M | -1.46M | -3.39M | -3.55M |
| EPS Basic | -1.04 | -1.03 | 0.62 | -737.87 | -12.41 |
| Normalized Basic EPS | -0.65 | -0.64 | 1.66 | -597.04 | -7.75 |
| EPS Diluted | -1.05 | -1.03 | -0.16 | -737.87 | -12.41 |
| Normalized Diluted EPS | -0.65 | -0.64 | 0.38 | -597.04 | -7.75 |
| Average Basic Shares Outstanding | 5.51M | 4.30M | 1.94M | 18.20K | 314.60K |
| Average Diluted Shares Outstanding | 5.51M | 4.30M | 8.37M | 18.20K | 314.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |